![](https://cdn.benzinga.com/files/images/story/2024/06/13/VANI.png?width=1200&height=800&fit=crop)
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical ...
Vivani Medical, Inc. VANI announced that the U.S. FDA has cleared its Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial. This study will assess the safety, tolerability, and …